Families of Protein Phosphatase 1 Modulators Activated by Protein Kinases A and C: Focus on Brain

Progress in Nucleic Acid Research and Molecular Biology

Volumn 79, Issue , 2005, Pages 371-404

  Liu, Qing Rong ^a   Gong, Jian Ping ^a   Uhl, George R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; NERVE PROTEIN; PHOSPHOPROTEIN; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE; PPP1R14C PROTEIN, HUMAN; PROTEIN; PROTEIN KINASE C;

ANIMAL; BRAIN; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; MUSCLE; REVIEW;

ANIMALS; BRAIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; ENZYME INHIBITORS; HUMANS; MUSCLES; NERVE TISSUE PROTEINS; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEINS; PROTEIN KINASE C; PROTEINS;

EID: 23944463981     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(04)79008-X     Document Type: Review

References (126)

1. Cohen P. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 58 (1989) 453-508
2. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., and Greengard P. DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
3. Greengard P., Allen P.B., and Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 23 (1999) 435-447
4. Ceulemans H., and Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol. Rev. 84 (2004) 1-39
5. Shenolikar S., and Nairn A.C. Protein phosphatases: Recent progress. Adv. Second Messenger Phosphoprotein Res. 23 (1991) 1-121
6. Aggen J.B., Nairn A.C., and Chamberlin R. Regulation of protein phosphatase-1. Chem. Biol. 7 (2000) R13-R23
7. Bollen M., and Stalmans W. The structure, role, and regulation of type 1 protein phosphatases. Crit. Rev. Biochem. Mol. Biol. 27 (1992) 227-281
8. Kisielow J., Nairn A.C., and Karjalainen K. TARPP, a novel protein that accompanies TCR gene rearrangement and thymocyte education. Eur. J. Immunol. 31 (2001) 1141-1149
9. Li L., Eto M., Lee M.R., Morita F., Yazawa M., and Kitazawa T. Possible involvement of the novel CPI-17 protein in protein kinase C signal transduction of rabbit arterial smooth muscle. J. Physiol. (Lond.) 508 (1998) 871-881
10. Eto M., Karginov A., and Brautigan D.L. A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes. Biochemistry 38 (1999) 16952-16957
11. Liu Q.R., Zhang P.W., Zhen Q., Walther D., Wang X.B., and Uhl G.R. KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J. Biol. Chem. 277 (2002) 13312-13320
12. Liu Q.R., Zhang P.W., Lin Z., Li Q.F., Woods A.S., Troncoso J., and Uhl G.R. GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem. J. 377 (2004) 171-181
13. Beullens M., Van Eynde A., Bollen M., and Stalmans W. Inactivation of nuclear inhibitory polypeptides of protein phosphatase-1 (NIPP-1) by protein kinase A. J. Biol. Chem. 268 (1993) 13172-13177
14. Van Eynde A., Wera S., Beullens M., Torrekens S., Van Leuven F., Stalmans W., and Bollen M. Molecular cloning of NIPP-1, a nuclear inhibitor of protein phosphatase-1, reveals homology with polypeptides involved in RNA processing. J. Biol. Chem. 270 (1995) 28068-28074
15. Hall K.U., Collins S.P., Gamm D.M., Massa E., DePaoli-Roach A.A., and Uhler M.D. Phosphorylation-dependent inhibition of protein phosphatase-1 by G-substrate. A Purkinje cell substrate of the cyclic GMP-dependent protein kinase. J. Biol. Chem. 274 (1999) 3485-3495
16. Park I.K., Roach P., Bondor J., Fox S.P., and DePaoli-Roach A.A. Molecular mechanism of the synergistic phosphorylation of phosphatase inhibitor-2. Cloning, expression, and site-directed mutagenesis of inhibitor-2. J. Biol. Chem. 269 (1994) 944-954
17. Mulkey R.M., Endo S., Shenolikar S., and Malenka R.C. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 369 (1994) 486-488
18. Nishi A., Snyder G.L., Nairn A.C., and Greengard P. Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons. J. Neurochem. 72 (1999) 2015-2021
19. Eto M., Ohmori T., Suzuki M., Furuya K., and Morita F. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J. Biochem. (Tokyo) 118 (1995) 1104-1107
20. Cohen P.T., Brewis N.D., Hughes V., and Mann D.J. Protein serine/threonine phosphatases; an expanding family. FEBS Lett. 268 (1990) 355-359
21. Ceulemans H., Stalmans W., and Bollen M. Regulator-driven functional diversification of protein phosphatase-1 in eukaryotic evolution. Bioessays. 24 (2002) 371-381
22. Cohen P., and Nimmo G.A. The purification and characterization of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Biochem. Soc. Trans. 6 (1978) 17-20
23. Aitken A., Bilham T., and Cohen P. Complete primary structure of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Eur. J. Biochem. 126 (1982) 235-246
24. Huang F.L., and Glinsmann W.H. Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur. J. Biochem. 70 (1976) 419-426
25. McLaren L., Boyle S., Mason J.O., and Bard J.B. Expression and genomic characterization of protein phosphatase inhibitor-1: a novel marker for mesothelium in the mouse. Mech. Dev. 96 (2000) 237-241
26. Liu H.T., Lin T.H., Kuo H.C., Chen Y.C., Tsay H.J., Jeng H.H., Tsai P.C., Shie F.K., Chen J.H., and Huang H.B. Identification of the alternative splice products encoded by the human protein phosphatase inhibitor-1 gene. Biochem. Biophys. Res. Commun. 291 (2002) 1293-1296
27. Endo S., Zhou X., Connor J., Wang B., and Shenolikar S. Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35 (1996) 5220-5228
28. Foulkes J.G., Cohen P., Strada S.J., Everson W.V., and Jefferson L.S. Antagonistic effects of insulin and beta-adrenergic agonists on the activity of protein phosphatase inhibitor-1 in skeletal muscle of the perfused rat hemicorpus. J. Biol. Chem. 257 (1982) 12493-12496
29. Bibb J.A., Nishi A., O'Callaghan J.P., Ule J., Lan M., Snyder G.L., Horiuchi A., Saito T., Hisanaga S., Czernik A.J., Nairn A.C., and Greengard P. Phosphorylation of protein phosphatase inhibitor-1 by Cdk5. J. Biol. Chem. 276 (2001) 14490-14497
30. Stralfors P., Hiraga A., and Cohen P. The protein phosphatases involved in cellular regulation. Purification and characterisation of the glycogen-bound form of protein phosphatase-1 from rabbit skeletal muscle. Eur. J. Biochem. 149 (1985) 295-303
31. Tulloch A.G., and Pato M.D. Turkey gizzard smooth muscle myosin phosphatase-III is a novel protein phosphatase. J. Biol. Chem. 266 (1991) 20168-20174
32. Huang K.X., and Paudel H.K. Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor. Proc. Natl. Acad. Sci. USA 97 (2000) 5824-5829
33. King M.M., Huang C.Y., Chock P.B., Nairn A.C., Hemmings Jr. H.C., Chan K.F., and Greengard P. Mammalian brain phosphoproteins as substrates for calcineurin. J. Biol. Chem. 259 (1984) 8080-8083
34. Walaas S.I., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J. Neurosci. 4 (1984) 84-98
35. Walaas S.I., Aswad D.W., and Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301 (1983) 69-71
36. Hemmings Jr. H.C., Nairn A.C., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1. J. Biol. Chem. 259 (1984) 14491-14497
37. Huang H.B., Horiuchi A., Watanabe T., Shih S.R., Tsay H.J., Li H.C., Greengard P., and Nairn A.C. Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2. J. Biol. Chem. 274 (1999) 7870-7878
38. El-Rifai W., Smith Jr. M.F., Li G., Beckler A., Carl V.S., Montgomery E., Knuutila S., Moskaluk C.A., Frierson Jr. H.F., and Powell S.M. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer. Res. 62 (2002) 4061-4064
39. Williams K.R., Hemmings Jr. H.C., LoPresti M.B., Konigsberg W.H., and Greengard P. DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1. J. Biol. Chem. 261 (1986) 1890-1903
40. Kurihara T., Lewis R.M., Eisler J., and Greengard P. Cloning of cDNA for DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. J. Neurosci. 8 (1988) 508-517
41. Zhen X., Torres C., Wang H.Y., and Friedman E. Prenatal exposure to cocaine disrupts D1A dopamine receptor function via selective inhibition of protein phosphatase 1 pathway in rabbit frontal cortex. J. Neurosci. 21 (2001) 9160-9167
42. Nishi A., Snyder G.L., and Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17 (1997) 8147-8155
43. Lindskog M., Svenningsson P., Fredholm B., Greengard P., and Fisone G. Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11 (1999) 2182-2186
44. Halpain S., Girault J.A., and Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 343 (1990) 369-372
45. Hemmings Jr. H.C., Greengard P., Tung H.Y., and Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310 (1984) 503-505
46. Desdouits F., Siciliano J.C., Greengard P., and Girault J.A. Dopamine- and cAMP-regulated phosphoprotein DARPP-32: Phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc. Natl. Acad. Sci. USA 92 (1995) 2682-2685
47. Girault J.A., Hemmings Jr. H.C., Williams K.R., Nairn A.C., and Greengard P. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J. Biol. Chem. 264 (1989) 21748-21759
48. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.H., Kwon Y.T., Girault J.A., Czernik A.J., Huganir R.L., Hemmings Jr. H.C., Nairn A.C., and Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402 (1999) 669-671
49. Lagercrantz J., Kedra D., Carson E., Nordenskjold M., Dumanski J.P., Weber G., and Piehl F. Sequence and expression of the mouse homologue to human phospholipase C beta3 neighboring gene. Biochem. Biophys. Res. Commun. 223 (1996) 335-340
50. Lagercrantz J., Carson E., Larsson C., Nordenskjold M., and Weber G. Isolation and characterization of a novel gene close to the human phosphoinositide-specific phospholipase C beta 3 gene on chromosomal region 11q13. Genomics 31 (1996) 380-384
51. Deng J.T., Sutherland C., Brautigan D.L., Eto M., and Walsh M.P. Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem. J. 367 (2002) 517-524
52. Erdodi F., Kiss E., Walsh M.P., Stefansson B., Deng J.T., Eto M., Brautigan D.L., and Hartshorne D.J. Phosphorylation of protein phosphatase type-1 inhibitory proteins by integrin-linked kinase and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 306 (2003) 382-387
53. Wang X.B., Funada M., Imai Y., Revay R.S., Ujike H., Vandenbergh D.J., and Uhl G.R. rGbeta1: A psychostimulant-regulated gene essential for establishing cocaine sensitization. J. Neurosci. 17 (1997) 5993-6000
54. Wang X.B., and Uhl G.R. Subtracted differential display: Genes with amphetamine-altered expression patterns include calcineurin. Brain. Res. Mol. Brain. Res. 53 (1998) 344-347
55. Scanlan M.J., Gout I., Gordon C.M., Williamson B., Stockert E., Gure A.O., Jager D., Chen Y.T., Mackay A., O'Hare M.J., and Old L.J. Humoral immunity to human breast cancer: Antigen definition and quantitative analysis of mRNA expression. Cancer. Immun. 1 (2001) 4
56. Mazurenko N., Attaleb M., Gritsko T., Semjonova L., Pavlova L., Sakharova O., and Kisseljov F. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol. Rep. 6 (1999) 859-863
57. Theile M., Seitz S., Arnold W., Jandrig B., Frege R., Schlag P.M., Haensch W., Guski H., Winzer K.J., Barrett J.C., and Scherneck S. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene. 13 (1996) 677-685
58. Shridhar V., Staub J., Huntley B., Cliby W., Jenkins R., Pass H.I., Hartmann L., and Smith D.I. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. Oncogene. 18 (1999) 3913-3918
59. Berrettini W.H., Alexander R., Ferraro T.N., and Vogel W.H. A study of oral morphine preference in inbred mouse strains. Psychiatr. Genet. 4 (1994) 81-86
60. Taniguchi H. Protein myristoylation in protein-lipid and protein-protein interactions. Biophys. Chem. 82 (1999) 129-137
61. Senba S., Eto M., and Yazawa M. Identification of trimeric myosin phosphatase (PP1M) as a target for a novel PKC-potentiated protein phosphatase-1 inhibitory protein (CPI17) in porcine aorta smooth muscle. J. Biochem. (Tokyo) 125 (1999) 354-362
62. Eto M., Wong L., Yazawa M., and Brautigan D.L. Inhibition of myosin/moesin phosphatase by expression of the phosphoinhibitor protein CPI-17 alters microfilament organization and retards cell spreading. Cell Motil. Cytoskeleton. 46 (2000) 222-234
63. Eto M., Senba S., Morita F., and Yazawa M. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI-17) in smooth muscle: its specific localization in smooth muscle. FEBS Lett. 410 (1997) 356-360
64. Watanabe Y., Ito M., Kataoka Y., Wada H., Koyama M., Feng J., Shiku H., and Nishikawa M. Protein kinase C-catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. Blood 97 (2001) 3798-3805
65. Yamawaki K., Ito M., Machida H., Moriki N., Okamoto R., Isaka N., Shimpo H., Kohda A., Okumura K., Hartshorne D.J., and Nakano T. Identification of human CPI-17, an inhibitory phosphoprotein for myosin phosphatase. Biochem. Biophys. Res. Commun. 285 (2001) 1040-1045
66. Wang H., Eto M., Steers W.D., Somlyo A.P., and Somlyo A.V. RhoA-mediated Ca2+ sensitization in erectile function. J. Biol. Chem. 277 (2002) 30614-30621
67. MacDonald J.A., Eto M., Borman M.A., Brautigan D.L., and Haystead T.A. Dual Ser and Thr phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by MYPT-associated kinase. FEBS Lett. 493 (2001) 91-94
68. Koyama M., Ito M., Feng J., Seko T., Shiraki K., Takase K., Hartshorne D.J., and Nakano T. Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett. 475 (2000) 197-200
69. Hamaguchi T., Ito M., Feng J., Seko T., Koyama M., Machida H., Takase K., Amano M., Kaibuchi K., Hartshorne D.J., and Nakano T. Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N. Biochem. Biophys. Res. Commun. 274 (2000) 825-830
70. Takizawa N., Koga Y., and Ikebe M. Phosphorylation of CPI17 and myosin binding subunit of type 1 protein phosphatase by p21-activated kinase. Biochem. Biophys. Res. Commun. 297 (2002) 773-778
71. Hayashi Y., Senba S., Yazawa M., Brautigan D.L., and Eto M. Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa. J. Biol. Chem. 276 (2001) 39858-39863
72. Ohki S., Eto M., Kariya E., Hayano T., Hayashi Y., Yazawa M., Brautigan D., and Kainosho M. Solution NMR structure of the myosin phosphatase inhibitor protein CPI-17 shows phosphorylation-induced conformational changes responsible for activation. J. Mol. Biol. 314 (2001) 839-849
73. Ohki S., Eto M., Shimizu M., Takada R., Brautigan D.L., and Kainosho M. Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation-site threonine residue. J. Mol. Biol. 326 (2003) 1539-1547
74. Hemmings Jr. H.C., Girault J.A., Nairn A.C., Bertuzzi G., and Greengard P. Distribution of protein phosphatase inhibitor-1 in brain and peripheral tissues of various species: comparison with DARPP-32. J. Neurochem. 59 (1992) 1053-1061
75. MacDougall L.K., Campbell D.G., Hubbard M.J., and Cohen P. Partial structure and hormonal regulation of rabbit liver inhibitor-1; distribution of inhibitor-1 and inhibitor-2 in rabbit and rat tissues. Biochim. Biophys. Acta 1010 (1989) 218-226
76. Gustafson E.L., Girault J.A., Hemmings Jr. H.C., Nairn A.C., and Greengard P. Immunocytochemical localization of phosphatase inhibitor-1 in rat brain. J. Comp. Neurol. 310 (1991) 170-188
77. Genoux D., Haditsch U., Knobloch M., Michalon A., Storm D., and Mansuy I.M. Protein phosphatase 1 is a molecular constraint on learning and memory. Nature 418 (2002) 970-975
78. Wendel B., and Hoehe M.R. The human mu opioid receptor gene: 5′ regulatory and intronic sequences [see comments]. J. Mol. Med. 76 (1998) 525-532
79. Zachariou V., Benoit-Marand M., Allen P.B., Ingrassia P., Fienberg A.A., Gonon F., Greengard P., and Picciotto M.R. Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1. Biol. Psychiatry 51 (2002) 612-620
80. Allen P.B., Hvalby O., Jensen V., Errington M.L., Ramsay M., Chaudhry F.A., Bliss T.V., Storm-Mathisen J., Morris R.G., Andersen P., and Greengard P. Protein phosphatase-1 regulation in the induction of long-term potentiation: heterogeneous molecular mechanisms. J. Neurosci. 20 (2000) 3537-3543
81. Gupta R.C., Mishra S., Rastogi S., Imai M., Habib O., and Sabbah H.N. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H2373-H2381
82. El-Armouche A., Pamminger T., Ditz D., Zolk O., and Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61 (2004) 87-93
83. El-Armouche A., Rau T., Zolk O., Ditz D., Pamminger T., Zimmermann W.H., Jackel E., Harding S.E., Boknik P., Neumann J., and Eschenhagen T. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. Faseb. J. 17 (2003) 437-439
84. Carr A.N., Schmidt A.G., Suzuki Y., del Monte F., Sato Y., Lanner C., Breeden K., Jing S.L., Allen P.B., Greengard P., Yatani A., Hoit B.D., Grupp I.L., Hajjar R.J., DePaoli-Roach A.A., and Kranias E.G. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22 (2002) 4124-4135
85. Ouimet C.C., Miller P.E., Hemmings Jr. H.C., Walaas S.I., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 4 (1984) 111-124
86. Foster G.A., Schultzberg M., Kokfelt T., Goldstein M., Hemmings Jr. H.C., Ouimet C.C., Walaas S.I., and Greengard P. Ontogeny of the dopamine and cyclic adenosine-3′:5′- monophosphate-regulated phosphoprotein (DARPP-32) in the pre- and postnatal mouse central nervous system. Int. J. Dev. Neurosci. 6 (1988) 367-386
87. Blau S., Daly L., Fienberg A., Teitelman G., and Ehrlich M.E. DARPP-32 promoter directs transgene expression to renal thick ascending limb of loop of Henle. Am. J. Physiol. 269 (1995) F564-F570
88. Fryckstedt J., Aperia A., Snyder G., and Meister B. Distribution of dopamine- and cAMP-dependent phosphoprotein (DARPP-32) in the developing and mature kidney. Kidney Int. 44 (1993) 495-502
89. Beckler A., Moskaluk C.A., Zaika A., Hampton G.M., Powell S.M., Frierson Jr. H.F., and El-Rifai W. Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer 98 (2003) 1547-1551
90. Mikkelsen J.D., and Gustafson E.L. Distribution of phosphatase inhibitor-1-immunoreactive neurons in the suprachiasmatic nucleus of the Syrian hamster. Brain Res. 623 (1993) 147-154
91. Alder R., and Barbas H. Complementary distribution of the phosphoproteins DARPP-32 and I-1 in the cerebellar system. Neuroreport 6 (1995) 2368-2372
92. Barbas H., Gustafson E.L., and Greengard P. Comparison of the immunocytochemical localization of DARPP-32 and I-1 in the amygdala and hippocampus of the rhesus monkey. J. Comp. Neurol. 334 (1993) 1-18
93. Eklof A.C., Holtback U., Svennilson J., Fienberg A., Greengard P., and Aperia A. Increased blood pressure and loss of anp-induced natriuresis in mice lacking DARPP-32 gene. Clin. Exp. Hypertens. 23 (2001) 449-460
94. Onn S.P., Fienberg A.A., and Grace A.A. Dopamine modulation of membrane excitability in striatal spiny neurons is altered in DARPP-32 knockout mice. J. Pharmacol. Exp. Ther. 306 (2003) 870-879
95. Svenningsson P., Fienberg A.A., Allen P.B., Moine C.L., Lindskog M., Fisone G., Greengard P., and Fredholm B.B. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J. Neurochem. 75 (2000) 248-257
96. Risinger F.O., Freeman P.A., Greengard P., and Fienberg A.A. Motivational effects of ethanol in DARPP-32 knock-out mice. J. Neurosci. 21 (2001) 340-348
97. Heyser C.J., Fienberg A.A., Greengard P., and Gold L.H. DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task. Brain. Res. 867 (2000) 122-130
98. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
99. Eto M., Bock R., Brautigan D.L., and Linden D.J. Cerebellar long-term synaptic depression requires PKC-mediated activation of CPI-17, a myosin/moesin phosphatase inhibitor. Neuron 36 (2002) 1145-1158
100. Somlyo A.P., and Somlyo A.V. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. (Lond.) 522 Pt. 2 (2000) 177-185
101. Webb R.C. Smooth muscle contraction and relaxation. Adv. Physiol. Educ. 27 (2003) 201-206
102. Kitazawa T., Eto M., Woodsome T.P., and Brautigan D.L. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J. Biol. Chem. 275 (2000) 9897-9900
103. Etter E.F., Eto M., Wardle R.L., Brautigan D.L., and Murphy R.A. Activation of myosin light chain phosphatase in intact arterial smooth muscle during nitric oxide-induced relaxation. J. Biol. Chem. 276 (2001) 34681-34685
104. Takahashi R., Nishimura J., Hirano K., Seki N., Naito S., and Kanaide H. Ca2+ sensitization in contraction of human bladder smooth muscle. J. Urol. 172 (2004) 748-752
105. Kolosova I.A., Ma S.F., Adyshev D.M., Wang P., Ohba M., Natarajan V., Garcia J.G., and Verin A.D. The role of CPI-17 in the regulation of endothelial cytoskeleton. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2 (2004) 970-980
106. Ozaki H., Yasuda K., Kim Y.S., Egawa M., Kanzaki H., Nakazawa H., Hori M., Seto M., and Karaki H. Possible role of the protein kinase C/CPI-17 pathway in the augmented contraction of human myometrium after gestation. Br. J. Pharmacol. 140 (2003) 1303-1312
107. Ohama T., Hori M., Sato K., Ozaki H., and Karaki H. Chronic treatment with interleukin-1beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle. J. Biol. Chem. 278 (2003) 48794-48804
108. Gong M.C., Cohen P., Kitazawa T., Ikebe M., Masuo M., Somlyo A.P., and Somlyo A.V. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J. Biol. Chem. 267 (1992) 14662-14668
109. Gong J.P., Liu Q.R., Zhang P.W., Wang Y., and Uhl G.R. Mouse brain localization of the protein kinase C-enhanced phosphatase 1 inhibitor KEPI (Kinase C-Enhanced PP1 Inhibitor). Neuroscience 132 (2005) 713-727
110. Bailey C.H., Giustetto M., Huang Y.Y., Hawkins R.D., and Kandel E.R. Is heterosynaptic modulation essential for stabilizing Hebbian plasticity and memory?. Nat. Rev. Neurosci. 1 (2000) 11-20
111. Munton R.P., Vizi S., and Mansuy I.M. The role of protein phosphatase-1 in the modulation of synaptic and structural plasticity. FEBS Lett. 567 (2004) 121-128
112. Morishita W., Connor J.H., Xia H., Quinlan E.M., Shenolikar S., and Malenka R.C. Regulation of synaptic strength by protein phosphatase 1. Neuron 32 (2001) 1133-1148
113. Waddell S. Protein phosphatase 1 and memory: Practice makes PP1 imperfect?. Trends Neurosci. 26 (2003) 117-119
114. Blitzer R.D., Wong T., Nouranifar R., Iyengar R., and Landau E.M. Postsynaptic cAMP pathway gates early LTP in hippocampal CA1 region. Neuron 15 (1995) 1403-1414
115. Blitzer R.D., Connor J.H., Brown G.P., Wong T., Shenolikar S., Iyengar R., and Landau E.M. Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP. Science 280 (1998) 1940-1942
116. Alberts A.S., Montminy M., Shenolikar S., and Feramisco J.R. Expression of a peptide inhibitor of protein phosphatase 1 increases phosphorylation and activity of CREB in NIH 3T3 fibroblasts. Mol. Cell. Biol. 14 (1994) 4398-4407
117. Bito H., Deisseroth K., and Tsien R.W. CREB phosphorylation and dephosphorylation: A Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell 87 (1996) 1203-1214
118. Ouimet C.C., da Cruz e Silva E.F., and Greengard P. The alpha and gamma 1 isoforms of protein phosphatase 1 are highly and specifically concentrated in dendritic spines. Proc. Natl. Acad. Sci. USA 92 (1995) 3396-3400
119. da Cruz e Silva E.F., Fox C.A., Ouimet C.C., Gustafson E., Watson S.J., and Greengard P. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J. Neurosci. 15 (1995) 3375-3389
120. Muly E.C., Greengard P., and Goldman-Rakic P.S. Distribution of protein phosphatases-1 alpha and -1 gamma 1 and the D(1) dopamine receptor in primate prefrontal cortex: Evidence for discrete populations of spines. J. Comp. Neurol. 440 (2001) 261-270
121. Desdouits F., Cheetham J.J., Huang H.B., Kwon Y.G., da Cruz e Silva E.F., Denefle P., Ehrlich M.E., Nairn A.C., Greengard P., and Girault J.A. Mechanism of inhibition of protein phosphatase 1 by DARPP-32: Studies with recombinant DARPP-32 and synthetic peptides. Biochem. Biophys. Res. Commun. 206 (1995) 652-658
122. Tountas N.A., Mandell J.W., Everett A.D., and Brautigan D.L. Juxtamembrane localization of the protein phosphatase-1 inhibitor protein PHI-1 in smooth muscle cells. Histochem. Cell. Biol. 121 (2004) 343-350
123. Wakula P., Beullens M., Ceulemans H., Stalmans W., and Bollen M. Degeneracy and function of the ubiquitous RVXF motif that mediates binding to protein phosphatase-1. J. Biol. Chem. 278 (2003) 18817-18823
124. Egloff M.P., Johnson D.F., Moorhead G., Cohen P.T., Cohen P., and Barford D. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J. 16 (1997) 1876-1887
125. Alessi D., MacDougall L.K., Sola M.M., Ikebe M., and Cohen P. The control of protein phosphatase-1 by targetting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Eur. J. Biochem. 210 (1992) 1023-1035
126. Eto M., Kitazawa T., and Brautigan D.L. Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits. Proc. Natl. Acad. Sci. USA 101 (2004) 8888-8893